2-(4-((2-fluorophenyl)sulfonyl)piperazin-1-yl)-N-(1H-pyrazol-3-yl)acetamide | 1350621-69-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(4-((2-fluorophenyl)sulfonyl)piperazin-1-yl)-N-(1H-pyrazol-3-yl)acetamide
• 英文别名: 2-[4-(2-fluorophenyl)sulfonylpiperazin-1-yl]-N-(1H-pyrazol-5-yl)acetamide
• CAS: 1350621-69-0
• 化学式: C₁₅H₁₈FN₅O₃S
• 分子量: 367.404
• InChiKey: FSDDYEPPFMTKJU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  107
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-氟苯磺酰氯 在 sodium carbonate 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 16.0h， 生成 2-(4-((2-fluorophenyl)sulfonyl)piperazin-1-yl)-N-(1H-pyrazol-3-yl)acetamide
  参考文献：
  名称：

  Structure–Activity Relationship Studies of Sulfonylpiperazine Analogues as Novel Negative Allosteric Modulators of Human Neuronal Nicotinic Receptors

  摘要：

  Neuronal nicotinic receptors have been implicated in several diseases and disorders such as autism, Alzheimer's disease, Parkinson's disease, epilepsy, and various forms of addiction. To understand the role of nicotinic receptors in these conditions, it would be beneficial to have selective molecules that target specific nicotinic receptors in vitro and in vivo. Our laboratory has previously identified novel negative allosteric modulators of human alpha 4 beta 2 (H alpha 4 beta 2) and human alpha 3 beta 4 (H alpha 3 beta 4) nicotinic receptors. The effects of novel sulfonylpiperazine analogues that act as negative allosteric modulators on both H alpha 4 beta 2 nAChRs and H alpha 3 beta 4 nAChRs were investigated. This work, through structure activity relationship (SAR) studies, describes the chemical features of these molecules that are important for both potency and selectivity on H alpha 4 beta 2 nAChRs.

  DOI：

  10.1021/jm201294r

文献信息

• Structure–Activity Relationship Studies of Sulfonylpiperazine Analogues as Novel Negative Allosteric Modulators of Human Neuronal Nicotinic Receptors
  作者：Brandon J. Henderson、Daniel J. Carper、Tatiana F. González-Cestari、Bitna Yi、Kiran Mahasenan、Ryan E. Pavlovicz、Martin L. Dalefield、Robert S. Coleman、Chenglong Li、Dennis B. McKay

  DOI：10.1021/jm201294r

  日期：2011.12.22

  Neuronal nicotinic receptors have been implicated in several diseases and disorders such as autism, Alzheimer's disease, Parkinson's disease, epilepsy, and various forms of addiction. To understand the role of nicotinic receptors in these conditions, it would be beneficial to have selective molecules that target specific nicotinic receptors in vitro and in vivo. Our laboratory has previously identified novel negative allosteric modulators of human alpha 4 beta 2 (H alpha 4 beta 2) and human alpha 3 beta 4 (H alpha 3 beta 4) nicotinic receptors. The effects of novel sulfonylpiperazine analogues that act as negative allosteric modulators on both H alpha 4 beta 2 nAChRs and H alpha 3 beta 4 nAChRs were investigated. This work, through structure activity relationship (SAR) studies, describes the chemical features of these molecules that are important for both potency and selectivity on H alpha 4 beta 2 nAChRs.